Vitamin D as an Adjuvant Therapy in Neonatal Hypoxia: Is it Beneficial?

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.

The aim of this study was to study the role of vitamin D as an adjuvant therapy for management of neonatal HIE.

Why It Was Studied

Extensive multicenter studies are required on a large number of patients with Sarnat grade II HIE with longer duration of follow up to give valid recommendations about the use of vitamin D as an adjuvant therapy in Sarnat grade II HIE.

Who Took Part

PubMed tags the participants as both men and women.

This study included also 30 healthy neonates as a control group.

All neonates included in this study were subjected to: complete clinical examination with assessment of Apgar score at 5 and 10 minutes, measurement of arterial blood gases and serum 25 (OH) vitamin D, calcium, phosphorus, S100-B and IL-17 levels.

How the Study Was Run

The design is described as multicenter.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

Group II: Included 30 neonates with HIE grade II who received erythropoietin and magnesium sulphate as group I but without vitamin D.

What Was Measured

Topics PubMed links to this paper include Asphyxia Neonatorum, Chemotherapy, Adjuvant, S100 Calcium Binding Protein beta Subunit and Vitamin D.

Author keywords: Hypoxic ischemic encephalopathy, S100-B, Vitamin D status, erythropoietin, neonates and seizures.

What This Means in Plain Language

The paper is a multicenter study of Vitamin D, K2, Magnesium and Zinc.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2019 (Endocrine, metabolic & immune disorders drug targets), a journal based in United Arab Emirates.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.